Reuters logo
5 个月前
BRIEF-Positive results from Replicel's RCS-01 phase I skin trial are the Company's most compelling to date
2017年4月4日 / 上午10点17分 / 5 个月前

BRIEF-Positive results from Replicel's RCS-01 phase I skin trial are the Company's most compelling to date

April 4 (Reuters) - Replicel Life Sciences Inc

* Positive results from Replicel's RCS-01 phase I skin trial are the company's most compelling to date

* Interim trial results lead researchers to conclude that injection of RCS-01 is not only very safe, but also has potential to reverse effects of aging skin Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below